These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4138250)

  • 21. Relationship of long-acting thyroid stimulator to the clinical features and course of Graves' disease.
    Lipman LM; Green DE; Snyder NJ; Nelson JC; Solomon DH
    Am J Med; 1967 Oct; 43(4):486-98. PubMed ID: 6072779
    [No Abstract]   [Full Text] [Related]  

  • 22. The long-acting thyroid stimulator: its role in Graves' disease.
    McKenzie JM
    Recent Prog Horm Res; 1967; 23():1-46. PubMed ID: 4174931
    [No Abstract]   [Full Text] [Related]  

  • 23. The production of thyroid-stimulating immunoglobulin (TSI) by lymphocytes from patients with Graves' disease cultured with human thyroid subcellular fractions.
    Sugenoya A; Trokoudes K; Row VV; Volpé R
    J Endocrinol Invest; 1978 Jul; 1(3):245-51. PubMed ID: 583156
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms of Graves' disease and endocrine exophthalmos.
    Anderson DR
    Am J Ophthalmol; 1969 Jul; 68(1):46-57. PubMed ID: 4895778
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-acting thyroid stimulator and thyroid function in relatives of patients with Graves' disease.
    Bonnyns M; Vanhaerlst L; Golstein J; Cauchie C; Ermans AM; Bastenie PA
    Clin Endocrinol (Oxf); 1973 Jul; 2(3):277-87. PubMed ID: 4128244
    [No Abstract]   [Full Text] [Related]  

  • 26. [Abnormality and deficiency in cellular immunity and internal diseases--Basedow's disease and cellular immunity].
    Shishiba Y
    Nihon Rinsho; 1978; 36(5):960-6. PubMed ID: 353330
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunological studies of the eye changes of thyrotoxicosis.
    Wall JR; Odgers R; Hetzel BS
    Aust N Z J Med; 1973 Apr; 3(2):162-8. PubMed ID: 4515114
    [No Abstract]   [Full Text] [Related]  

  • 28. Isoelectric focusing of thyroid-stimulating antibody of Graves' disease.
    Zakarija M; McKenzie JM
    Endocrinology; 1978 Oct; 103(4):1469-75. PubMed ID: 33803
    [No Abstract]   [Full Text] [Related]  

  • 29. Relationship between the long-acting thyroid stimulator and circulating thyroid antibodies in Graves' disease.
    Pinchera A; Liberti P; De Santis R; Grasso L; Martino E; Baschieri L
    J Clin Endocrinol Metab; 1967 Dec; 27(12):1758-60. PubMed ID: 6072765
    [No Abstract]   [Full Text] [Related]  

  • 30. Pathogenesis and therapy of neonatal graves disease.
    Fisher DA
    Am J Dis Child; 1976 Feb; 130(2):133-4. PubMed ID: 766612
    [No Abstract]   [Full Text] [Related]  

  • 31. The immunologic basis of Graves's disease.
    Volpé R
    N Engl J Med; 1972 Aug; 287(9):463-4. PubMed ID: 5068098
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypothyroidism after treatment with sodium iodide I-131. Incidence and relationship to antithyroid antibodies, long-acting thyroid stimulator (LATS), and infiltrative ophthalmopathy.
    Burke G; Silverstein GE
    JAMA; 1969 Nov; 210(6):1051-8. PubMed ID: 4900342
    [No Abstract]   [Full Text] [Related]  

  • 33. Letter: Nomenclature of thyroid-stimulating antibodies.
    Adams DD; Dirmikis S; Doniach D; El Kabir DJ; Hall R; Ibbertson HK; Irvine WJ; Kendall-Taylor P; Manley SW; Mehdi SQ; Munro DS; Purves HD; Smith BR; Stewart RD
    Lancet; 1975 May; 1(7917):1201. PubMed ID: 48829
    [No Abstract]   [Full Text] [Related]  

  • 34. [Significance of long-acting thyroid stimulator. Reflections on the 1st series of results].
    Tourneur R; Letonturier P; Sénécal P
    Minerva Med; 1974 Mar; 65(19):995-8. PubMed ID: 4406464
    [No Abstract]   [Full Text] [Related]  

  • 35. L.A.T.S. and Graves' disease.
    Hedley AJ; Ross IP; Crooks J
    Lancet; 1970 Aug; 2(7670):468-9. PubMed ID: 4195146
    [No Abstract]   [Full Text] [Related]  

  • 36. Cell-mediated immunity in Graves' disease and in Hashimoto's thyroiditis as shown by the demonstration of migration inhibition factor (MIF).
    Lamki L; Row VV; Volpé R
    J Clin Endocrinol Metab; 1973 Feb; 36(2):358-64. PubMed ID: 4739173
    [No Abstract]   [Full Text] [Related]  

  • 37. Endocrine exophthalmos: an immunologic aberration.
    Kaplan HJ
    Ophthalmic Semin; 1977; 2(2):203-46. PubMed ID: 327376
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-acting thyroid stimulator and related factors.
    Kendall-Taylor P; Dirmikis SM; Munro DS
    Proc R Soc Med; 1975 Apr; 68(4):252-3. PubMed ID: 1242809
    [No Abstract]   [Full Text] [Related]  

  • 39. [TSH-receptor-bound antithyroid antibody and the etiology of Basedow's disease].
    Shishiba Y
    Nihon Rinsho; 1983; 41(4):801-7. PubMed ID: 6310180
    [No Abstract]   [Full Text] [Related]  

  • 40. Familial incidence of long-acting thyroid stimulator (LATS) in Graves' disease.
    Bonnyns M; Vanhaelst L
    Horm Metab Res; 1972 Mar; 4(2):132. PubMed ID: 5067566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.